Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

LEKTI is crucial for skin barrier and immune function, affecting conditions like Netherton syndrome and atopic dermatitis.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Cepharanthine can potentially treat gastric cancer by stopping tumor growth.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

EGFR inhibitors can cause unusual localized hair growth.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Cubosomal gels enhance skin absorption of cetirizine better than niosomal gels.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Skin debridement and antifungals successfully treated severe scalp infection without scarring.

Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.

Gefitinib can cause hair and eyebrow darkening.

Tideglusib helps heal wounds in older skin.

Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.